新型冠状病毒肺炎(Novel coronavirus pneumonia,曾用简称NCP，后修订为COVID-19)是指由新型冠状病毒引起的以发热、咳嗽、头痛、乏力、呼吸困难等症状为主要临床表现的病毒型肺炎。最早的COVID-19患者被发现于武汉，患者从感染到发病通常在14天内，该病毒具有较强的传染性。截止至2020.2.23, COVID-19患者累计77049例，导致不少于2445位患者死亡。与SARA相比，新冠状状肺炎进展快，危重患者多存在肺损伤、肝功能异常、急性呼吸窘迫综合征、最终发展至多器官衰竭、休克。危重COVID-19患者的病理机制目前仍未阐释清楚，有学者从新型冠状病毒引起的炎症瀑布揭示COVID-19患者肝功能异常。COVID-19病理发展变化最终需要详实的解剖病理研究证实。COVID-19给我国造成的危害不亚于2003年我国爆发的SARA。在当前COVID-19防治工作中，仍未形成全球公认最佳疗效的治疗指南，现代医学与传统医学救治措施的均有报道。本文将COVID-19的最新中西医防治方法和措施予以汇总，为COVID-19防治工作提供支持。
Novel coronavirus pneumonia (CVID-19) refers to viral pneumonia caused mainly by fever, cough, headache, fatigue, and dyspnea caused by the new coronavirus. The earliest patient with COVID-19 was found in Wuhan. The infection is usually within 14 days. The virus is highly contagious. As of February 23, 2020, a total of 77,049 COVID-19 patients were confirmed diagnosis, resulting in no less than 2445 patients death. Compared with SARA, neo-coronary pneumonia progresses faster, and critically ill patients often have lung injury, liver dysfunction, acute respiratory distress syndrome, and eventually develop multiple organ failure and shock. The pathological mechanism of critically ill patients with COVID-19 is still unclear, and some scholars have revealed abnormal liver function in patients with COVID-19 from the waterfall of inflammation caused by the 2019-nCoV. The pathological development of COVID-19 needs to be confirmed by detailed anatomic and pathological studies. The damage caused by COVID-19 to our country is no less than that of the outbreak of SARA in China in 2003. In the current COVID-19 prevention and treatment work, there is still no globally accepted treatment guideline for the best curative effect, and modern and traditional medical treatment measures have been reported. This article summarizes the latest Chinese and Western medicine prevention methods and measures for COVID-19, and provides support for the prevention and treatment of COVID-19.